

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Christopher B. Linder on May 30, 2008.

Examiner's Amendments to the Claims:

Please enter the following amendments to the claims:

1. (Currently amended) A pharmaceutical composition comprising:
an isolated SED1 polypeptide having an amino acid sequence selected from
SEQ ID NOs: 2, 4, 5, 6, or 7, wherein the polypeptide is in an amount effective to inhibit
mammalian gamete adhesion, ~~or in an amount effective to promote mammalian gamete~~
~~adhesion.~~

2. (Canceled).

3. (Previously presented) The composition of claim 1, further comprising a
pharmaceutically acceptable carrier or excipient.

4. (Previously presented) The composition of claim 1, wherein the polypeptide
competitively inhibits in vivo or in vitro binding of sperm to unfertilized zona pellucida.

5-7. (Canceled).

8. (Previously presented) The composition of claim 1, wherein the isolated SED1
polypeptide_compound binds to male gametes, female gametes, male and female gametes, zona
pellucida, or combinations thereof.

9. (Previously presented) The composition of claim 1, wherein the isolated SEDI polypeptide is a recombinant polypeptide.

10-52. (Canceled)

Examiner's Amendments to the Specification:

Please replace paragraph 1 at page 1 with the following:

----This application is a national stage application of PCT/US04/34391, filed October 18, 2004, which claims benefit of and priority to US Provisional Patent entitled "Therapeutic Applications of SEDI" Application No. 60/512,174 filed on October 17, 2003, and where permissible, is incorporated by reference in its entirety. ----

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Kathleen Kerr Bragdon can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1656

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Karen Cochrane Carlson, Ph.D./
Primary Examiner, Art Unit 1656